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Summary of thesis 
Non-living antigens are often poorly immunogenic and require addition of adjuvants to 
elicit protective immunity. Due to the immunostimulatory potential of Toll-like receptor 
(TLR) ligands, they are explored as vaccine adjuvants. The development of efficient and 
cheap vaccines against aquatic viruses is important for a sustainable aquaculture industry 
and the adjuvants for fish vaccines need to be improved. However, increased knowledge of 
fish TLR function is required before their ligands can find their way into fish vaccines. 
The major aim if this thesis has been to contribute to a more detailed understanding of fish 
TLRs. First, the tissue distribution of all known Atlantic salmon TLRs, the 
immunostimulatory potential of a panel of TLR ligands in primary head kidney leucocytes, 
and the impact of viral infection on TLR expression in head kidney were investigated. 
Head kidney and spleen were the main TLR expressing organs in Atlantic salmon. Several 
TLR ligands induced expression of inflammatory cytokines in salmon head kidney 
leucocytes. TLR3, TLR7, and TLR8a1 were induced in vivo after viral infection. In order 
to functionally validate ligand-specific activation of fish TLRs, we established an in vitro 
reporter assay in a salmon cell line. However, classical TLR2 ligands failed to activate 
rainbow trout TLR2 signalling when using NF-κB activation as measure of activation. To 
test the in vivo immunostimulatory potential of a TLR ligand alone and in vaccine 
formulations, a cold-water zebrafish challenge model was used. The TLR3 ligand poly I:C 
induced expression of antiviral transcripts in zebrafish head kidney and pre-treatment with 
poly I:C delayed VHSV (viral haemorrhagic septicaemia virus)-induced mortality. 
Chitosan encapsulated poly I:C was demonstrated to provide protection against VHSV 
when co-injected with two different non-living antigens (inactivated whole VHSV and 
VHSV glycoprotein G). Due to decreasing levels of the dietary n-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in Atlantic salmon feed, we 
investigated how minimal levels of these fatty acids affect TLR signalling in Atlantic 
salmon leucocytes. The ability of leucocytes to respond to TLR ligand stimuli was reduced 
with low dietary- and head kidney levels of EPA and DHA, indicating the importance of n-
3 fatty acids in resistance to infection and response to vaccines.  
Our results provide new knowledge in the fish TLR field and lend support to poly I:C as a 
promising adjuvant candidate in viral vaccines. 
Sammendrag (Summary in Norwegian)
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Sammendrag (Summary in Norwegian) 
Adjuvanser er en gruppe substanser som ofte brukes for å øke immunogenisiteten til 
vaksineantigener uten egen replikasjon (inaktiverte virus og rekombinante proteiner). 
Ligander som gjenkjennes av Toll-lignende reseptorer (TLR) stimulerer immunstemet og 
utforskes som potensielle nye adjuvanser i humane vaksiner. Det er behov for bedre 
virusvaksiner og nye adjuvanser til bruk i den globale akvakulturnæringen. For å kunne 
fullt utnytte den stadig økende informasjon om TLR og TLR-ligander i vaksiner til andre 
arter, må man øke kunnskapen om TLR i fisk. Hovedmålet med denne avhandlingen var 
derfor å bidra til økt forståelse om TLR i fisk. I artikkel 1, undersøkte vi distribusjonen av 
alle kjente TLR i atlantisk laks, hvordan hodenyre leukocytter responderte på stimulering 
med TLR-ligander og hvordan genuttrykket av TLR ble endret under en virusinfeksjon. 
Hodenyre og milt var de organene som uttrykte høyeste nivåer av de fleste TLR, og flere 
av TLR-ligandene induserte økt uttrykk av inflammatoriske cytokiner i leukocytter fra 
hodenyre. TLR3, TLR7 og TLR8a1 ble oppregulert ved virussykdommen infeksiøs 
lakseanemi i laks. For å kunne måle ligandbinding til TLR fra fisk (artikkel 2), etablert et 
cellesystem basert på målinger av NF-κB-aktivitet (et nedstrøms signalprotein). TLR2 fra 
regnbueørret lot seg ikke aktivere med klassiske TLR2-ligander i dette systemet. Sebrafisk 
ble også brukt for å teste immunstimulerende effekt av en TLR-ligand og til utprøving av 
vaksiner basert på TLR-ligand formulert i nanopartikler (artikkel 3 og 4).  TLR3-liganden 
poly I:C økte uttrykket av flere immungener i sebrafisk som er viktige i bekjempelsen av 
virussykdommer, samt at løselig poly I:C forsinket dødeligheten etter at fiskene var infisert 
med VHS (viral hemoragisk septikemi)-virus. Vaksiner som inneholdt poly I:C innkapslet i 
chitosan partikler kombinert med enten et inaktivert VHS-virus eller glykoprotein fra 
VHS-virus beskyttet sebrafisken fra VHS. Dette viser at poly I:C er en lovende adjuvans i 
virusvaksiner. På grunn av økt etterspursel etter eicosapentaensyre (EPA) og 
docosahexaensyre (DHA), har innholdet av disse omega-3 fettsyrene i laksefôr blitt kraftig 
redusert. Vi undersøkte derfor hvordan minimale nivåer av disse fettsyrene påvirker 
leukocytter fra atlantisk laks. Leukocytter fra gruppen som ble fôret med de laveste 
nivåene av EPA og DHA viste redusert evne til å respondere på TLR-ligander. Dette 
indikerer viktigheten av omega-3 fettsyrer for å bekjempe infeksjoner og evnen til å 
respondere optimalt på vaksiner.  
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Introduction  
1. Vaccines 
1.1. A brief history of vaccines 
During the last century, vaccination has had a tremendous impact on global health by 
reducing death and morbidity caused by infectious diseases. Vaccines are biological 
preparations that enhance immunity against disease and either prevent (prophylactic 
vaccines) or treat disease (therapeutic vaccines) (Delany et al., 2014). The principle of 
vaccination was first applied over 1000 years ago via the process of “variolation”; the 
inoculation of pustules from smallpox patients into healthy individuals who were then 
subsequently protected against the disease (Riedel, 2005). The British vaccine pioneer 
Edward Jenner developed the process further in the 1790s by showing that exposure to 
cowpox induces protective immunity to smallpox (the term “vaccination” is derived from 
the Latin words for cow and cowpox - vacca and vaccinia). This discovery led to a decline 
in smallpox mortality and, many years later, the eradication of smallpox in 1977 (Riedel, 
2005, Minor, 2015). Since then there have been major advances in vaccine development. 
Louis Pasteur’s principles “isolate, inactivate and inject” in the late 1800s led to the 
development of successful vaccines, based on inactivated toxins and live attenuated or 
inactivated (killed) pathogens, against many serious infectious diseases (Rappuoli, 2007, 
Plotkin, 2005). From 1950, many new effective inactivated, live attenuated, and subunits 
vaccines have been developed as a result of the progress in microbiology and gene 
technology.  
1.2. Human viral vaccines 
Live attenuated vaccines against viral diseases are one of the most cost effective health 
interventions currently available (Bloom et al., 2005). Poliomyelitis, measles, mumps, 
yellow fever, and rubella are examples of diseases that can be prevented by licensed live 
attenuated vaccines (Minor, 2015). Poliomyelitis is nearly eradicated, and measles and 
mumps are controlled in the western world (Minor, 2015). Live vaccines are generally very 
effective and induce long-lived immunity after only one single dose. Attenuation can be 
achieved by serial passages of the virus in cultured cells, applying harsh condition on a 
Introduction
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virus strain, or using recombinant gene technology (Rappuoli et al., 2009, Kallerup and 
Foged, 2015). The viral strain will accumulate mutations that make it non-pathogenic, 
while it still possesses patterns of the original virus and mimics the natural infection by 
inducing an immune response (Clem, 2011). Today, the further development of these 
vaccines is limited by several safety concerns, e.g. risk of reversion to the virulent strain, 
disease in immunocompromised individuals, and spread of the attenuated virus into the 
environment (Lauring et al., 2010).  
The safety concerns of live attenuated vaccines have led to a shift towards inactivated 
viruses or viral subunits as vaccines. Inactivated vaccines are generally less immunogenic 
than their live attenuated counterparts due to the lack of replication and fast clearance from 
the injection site; hence the often need for an additional booster dose and adjuvants. 
However, such vaccines are more stable and safer than live vaccines. Inactivated vaccines 
are produced by viral cultivation to produce large quantities of the antigen and then 
inactivation by radiation, heat, or chemical agents. Inactivated vaccines usually do not 
require refrigeration, and they can be easily stored and transported in freeze-dried form, 
which makes them more accessible to people in developing countries (Sanders et al., 
2015). 
Subunit vaccines contain one or more components of a pathogen rather than the entire 
pathogen (like a protein, polysaccharide, glycoprotein, inactivated toxin, or outer 
membrane vesicle). The antigens are chosen because of their ability to elicit protective 
immunity. Production is more easily controlled and they offer considerable advantages 
over the inactivated and attenuated vaccines in terms of safety. Because of the lack of 
many pathogen features, these subunit vaccines are weakly immunogenic and often require 
co-administration of an adjuvant (Kallerup and Foged, 2015). Virus-like particles (VLPs) 
are derived from self-assembling subunits of viral structural proteins that mimic the 
structure of an authentic virus, but lack the viral genome. Vaccines consisting of VLPs 
combine the advantages of whole virus vaccines (strong immune response) and 
recombinant subunit vaccines (safe and simple vaccine). Several licensed VLP vaccines 
are available, e.g. against human papilloma virus and hepatitis B virus. These vaccines 
consist of one or more viral proteins (expressed in yeast, insect, or mammalian cells) that 
are important for inducing antibodies against the virus (Roldão et al., 2010).  
Introduction
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DNA vaccines deliver genetic material that encodes a specific antigen to the skin or the 
muscle. The DNA enters local cells and uses the host cellular machinery to express the 
antigen encoded in the DNA vaccine. The synthesised antigen can then be presented in the 
major histocompatibility complex (MHC) for T and B cells to initiate immune responses. 
Two viral DNA vaccines are licensed (vaccines against West Nile virus and infectious 
hematopoietic necrosis virus for use in horses and salmon respectively), and several DNA 
vaccines are currently tested in clinical trials (Kutzler and Weiner, 2008). It is also possible 
to use replicating or non-replicating viruses as vaccine vectors. The virus vector is a non-
pathogenic virus that has been modified to encode and present antigens from a pathogen. A 
wide range of innovative viral vectors that are able to deliver antigens and induce immune 
responses are available (e.g. pox viruses, adenovirus, coronavirus, flavivirus, influenza 
virus, rhabdovirus etc. (Draper and Heeney, 2010). 
1.3. The need for viral vaccines in fish farming 
Aquaculture (farming of aquatic organisms) is a rapidly growing global industry and an 
important nutritional and economical source for many countries around the world, 
especially in Asia and South America. The aquaculture industry is also of great importance 
to Norway. In the late 1960s, salmon farming started in Norway to support rural fishing 
communities that were having economic problems due to reduction in wild-capture fishing 
activity (Liu et al., 2011). Since then the aquaculture industry has overcome many 
technical and biological challenges and has become one of Norway’s biggest export trades 
after oil and gas. The main species of Norwegian aquaculture today are salmonid fish 
(Atlantic salmon Salmo salar and rainbow trout Oncorhynchus mykiss). Today, Norway is 
the largest producer and exporter of Atlantic salmon globally, followed by Chile, United 
Kingdom, and Canada. In 2014, the total amount of produced Atlantic salmon in Norway 
exceeded 1.2 million tonnes, which constituted over 50 % of the total world production of 
this fish (Guttormsen, 2015). 
Although aquaculture is one of the fastest growing food-producing industries in the world, 
there are still challenges that pose a threat to a sustainable growth of this industry. One of 
the major challenges is infectious diseases caused by bacteria, viruses, and parasites, 
whose detrimental impacts are facilitated by the effectiveness of pathogen transportation in 
water and the high density of fish in large-scale farming. Diseases can lead to great 
production losses, unacceptable animal welfare situations, and spread of disease to wild 
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fish in the area. Worldwide the most common pathogens causing infectious diseases are 
bacteria (over 50%), followed by viruses, parasites and fungi (Kibenge et al., 2012). 
Today, in Northern Europe and North America, bacterial diseases are controlled by 
vaccines in most salmonid farms and the use of antibiotics is limited (Sommerset et al., 
2005). However, viral diseases have been more difficult to control due to lack of antiviral 
therapeutics, high susceptibility of fish during the early stages of the life cycle, and 
insufficient knowledge about pathogenesis and natural resistance to viral infections. The 
development of efficient viral vaccine has also been a challenge (Kibenge et al., 2012). 
Both farmed and wild fish are susceptible to a long list of viral pathogens. Some of the 
most important viral diseases and the causative viruses affecting farmed fish are listed in 
Table 1 (Kibenge et al., 2012, Crane and Hyatt, 2011, Dhar et al., 2014, Shoemaker et al., 
2015). Eight viral fish diseases are listed as reportable diseases by the World Organization 
for Animal Health (OIE) in 2015 due to the risk of viral spread through commercial trade 
of fish and fish products (see Table 1) (Dhar et al., 2014). In Norway, pancreas disease 
(PD), heart and skeletal muscle inflammation (HSMB), infectious pancreatic necrosis 
(IPN), cardiomyopathy syndrome (CMS), and infectious salmon anaemia (ISA) are the 
most frequent viral diseases detected in farmed fish (Veterinærinstituttet, 2015).  
Viral haemorrhagic septicaemia (VHS) is one of the oldest prevailing and most 
economically important viral diseases of salmonid fish in Europe and flounder in Asia. No 
vaccine is available, and the disease is reportable to OIE indicating the importance of this 
virus. The causative agent of VHS, viral haemorrhagic septicaemia virus (VHSV) is a 
single stranded RNA virus and member of the family Rhabdoviridae and genus 
Novirhabdovirus. The virus has five major structural proteins (nucleocapsid-, phospho-, 
matrix-, glyco- and RNA polymerase protein) and there are currently four genotypes 
identified (genotype I-IV) (Einer-Jensen et al., 2004, Skall et al., 2005). The most 
susceptible fish species is the rainbow trout, but the virus has since the first identification 
in the early 1900s been isolated from numerous wild and farmed fish species (Skall et al., 
2005). VHSV causes high mortality rates (up to 100% in fry) and huge economical losses 
(Crane and Hyatt, 2011, Micol et al., 2005). 
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1.4. Current status of fish vaccines 
The success of bacterial vaccines in fish have led to a decrease in the use of antibiotics, and 
several vaccines against bacterial diseases are used in aquaculture worldwide (Håstein et 
al., 2005). In Norway, bacterial diseases caused enormous losses to the salmon farming 
during the 1980s and tonnes of antibiotics were used (Figure 1). However, due to the 
introduction of effective bacterial vaccines and improved health management, the total 
consumption of antimicrobials was reduced by 99% and made it possible for the huge 
increase in production (NORM/NORM-VET2013, 2013). Today in Norway, the salmonid 
population is vaccinated against three major bacterial diseases (vibriosis, cold-water 
vibriosis, and furunculosis) before release into sea water. Worldwide vaccination has been 
most important in salmonids and species like sea bass (Dicentrarchus labrax) and sea 
bream (Sparus aurata) (Håstein et al., 2005). The main administration routes for fish are 
injection and immersion. Oral vaccines have also been used, but have not provided the 
same efficiency as immersion and injectable vaccines. The bacterial vaccines in use are 
simple, consisting of formalin-inactivated whole bacteria. Many of the registered vaccines 
Table 1: List of viral diseases impacting farmed fish   
Disease Causative virus Virus family Host examples 
Infectious pancreatic necrosis 
(IPN)* 
Infectious pancreatic necrosis virus 
(IPNV) 
Birnaviridae Salmonids, halibut, 
common carp 
Viral encephalopathy and 
retinopathy (VER) or Viral 
nervous necrosis  (VNN) 
Nervous necrosis virus (NNV) Nodaviridae Atlantic halibut,  
Atlantic cod, sea 
bass, grouper 
Infectious salmon anaemia 
(ISA)*a 
Infectious salmon anaemia virus 
(IAV) 
Orthomyxoviridae Salmonids  
Pancreas disease (PD) or 
sleeping disease (SD)*a 
Salmon alpha virus (SAV) Togaviridae Atlantic salmon, 
rainbow trout 
Infectious hematopoietic 
necrosis (IHN)a 
Infectious hematopoietic necrosis 
virus (IHNV) 
Rhabdoviridae Salmonids, 
sturgeon, herring 
Epizootic hematopoietic 
necrosis (EHN)a 
Epizootic hematopoietic necrosis 
virus (EHNV) 
Iridoviridae Rainbow trout, 
perch species 
Viral haemorrhagic 
septicaemia (VHS)*a 
Viral haemorrhagic septicaemia 
virus (VHSV) 
Rhabdoviridae Rainbow trout, 
turbot, flounder 
Spring viremia of carp (SVC)a Spring viremia of carp virus (SVCV) Rhabdoviridae Carp species 
Cardiomyopathy syndrome 
(CMS)* 
Piscine myocarditis virus (PMCV) Totiviridae Atlantic salmon 
Heart and skeletal muscle 
inflammation (HSMI)* 
Piscine reovirus (PRV) (suspected) Reoviridae Atlantic salmon 
Koi herpesvirus disease 
(KHVD)a 
Koi herpesvirus (KHV) Alloherpesviridae Common carp, Koi 
Red sea bream iridoviral 
disease (RSID)a 
Red sea bream iridovirus (RSIV) Iridoviridae Sea bream species  
*Diseases reported in Norway.  
a Listed as reportable fish diseases by The World Organisation for Animal Health (OIE). 
References (Kibenge et al., 2012, Crane and Hyatt, 2011, Dhar et al., 2014, Shoemaker et al., 2015) 
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are multivalent, i.e. they protect fish against more than one bacterial disease. To obtain 
satisfactory protection, adjuvants are included in the vaccines (Håstein et al., 2005). 
 
Figure 1: Amount of antibiotics (tonnes) for therapeutic use in farmed fish in Norway versus 
produced biomass farmed fish (1,000 tonnes) (NORM/NORM-VET2013, 2013). The arrows mark 
the introduction of bacterial vaccines (Sommerset et al., 2005). 
 
Although vaccination against diseases in aquaculture has enabled control of many bacterial 
diseases, the development of efficient and cheap vaccines against viral diseases has proven 
very challenging. The few existing vaccines for viral diseases in fish are either monovalent 
vaccines or included in multivalent bacterial vaccines. Live attenuated vaccines induce 
strong and sustained immune responses to the target disease in fish, but there are 
environmental and regulatory concerns hampering their further development. Most 
aquaculture operations are without physical barriers to wild-living fish in the same area 
and strains attenuated for aquaculture species may be virulent in wild species living in farm 
areas (Dhar et al., 2014, Salgado-Miranda et al., 2013, Brudeseth et al., 2013).  
The majority of the commercial viral vaccines are based on inactivated virus and target 
salmonid viruses like infectious pancreatic necrosis virus (IPNV), infectious salmon 
anaemia virus (ISAV), and salmon alphavirus (SAV) (Dhar et al., 2014). However, many 
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attempts to make inactivated viral vaccines (although adjuvanted) have failed due to low 
immunogenicity. In addition, some viruses display poor or non-existent replication in cell 
cultures, making it difficult to grow sufficient quantities of antigen for vaccine production. 
A few subunit vaccines are available against IPN and ISA, and consist of a capsid protein 
(VP2) of IPNV and the ISAV recombinant hemagglutinin esterase gene, respectively. One 
DNA vaccine, based on the gene of IHNV glycoprotein, is licensed in Canada, but is not 
approved in Europe or the United States due to safety concerns regarding the integration of 
foreign genes in food (Evensen and Leong, 2013). Although the licensed viral vaccines 
have been documented to be effective in experimental trials, the efficacy of these vaccines 
under field condition is uncertain due to a lack of published reports and continued 
occurrence of viral outbreaks (Rimstad, 2014, Robertsen, 2011, Kibenge et al., 2012, 
Rimstad, 2011, Veterinærinstituttet, 2015). 
Like the inactivated bacterial vaccines, the inactivated virus and viral subunits are non-
replicating antigens resulting in lower immunogenicity and often need to be accompanied 
by adjuvants. The oil-based adjuvants included in the available fish vaccines can lead to 
severe adverse effects (covered in section 2.2.). The list of subunit- (both recombinant 
protein and VLP) and DNA vaccines under development for fish is long, but the success of 
these vaccines is dependent on adjuvant improvements (Tafalla et al., 2013).  
2. Vaccine adjuvants 
2.1. Development of adjuvants for use in humans 
Non-living vaccine antigens (inactivated- and subunit vaccines) are often poorly 
immunogenic and will require development of adjuvants that can stimulate induction of 
protective humoral- and cell-mediated immunity (Coffman et al., 2010). Adjuvants (from 
latin adjuvare meaning “to help”) are a class of substances with a shared feature of 
increasing the immunogenicity and the efficacy of vaccines. The principle was first used 
by Gaston Ramon at Institute Pasteur in the 1920s and traditional adjuvants have been 
developed empirically, without a clear understanding of cellular and molecular 
mechanisms of action (Kenney and Cross, 2009). Vaccine adjuvants are a heterogeneous 
group of substances with a wide variety of mechanisms of action and recent research on 
vaccine development has focused on adjuvant improvement. Recent evidence suggests that 
adjuvants work through one or more of the following mechanisms: sustained release of 
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antigen, upregulation of cytokines and chemokines, increased antigen uptake and 
presentation, activation of inflammasomes, and activation, maturation and migration of 
antigen presenting cells (Cox and Coulter, 1997, Awate et al., 2013).  
The dominating adjuvants in licensed vaccines are aluminium salts (aluminium hydroxide 
or aluminium phosphate). Although aluminium salts have been used in vaccines for over 
80 years, their mechanism of action is not completely understood. Depot effect (sustained 
release) and inflammasome activation are among the proposed mechanisms (Kool et al., 
2008, Marrack et al., 2009). However, it is well-known that aluminium adjuvants induce 
production of local cytokines and chemokines, increase cell recruitment and antigen 
presentation that induce a type 2 T helper cell (Th2) skewed response, and increase 
antibody production (Marrack et al., 2009, Awate et al., 2013). Other adjuvants are based 
on oils (often emulsions), liposomes, microparticles, surface-active agents, pathogen- and 
plant derivatives, vitamins, or cytokines. However, most of them yet to be included in 
licensed vaccines and remain in experimental use (Kenney and Cross, 2009).  
The benefits of using an adjuvant are many, e.g. increased antibody titre and protective 
immunity, dose sparing, reduced number of immunisations (increased immunological 
memory), increased effect in populations with low response (e.g. elderly and children), 
enabling a more rapid immune response (post-exposure prophylaxis), antibody response 
broadening, and induction of a desired immune response against the specific pathogen (e.g. 
cell-mediated versus humoral response) (Coffman et al., 2010, Reed et al., 2013).  
A shift from empiricism to rational design of adjuvants in human vaccinology research has 
led to several new, efficient adjuvants in vaccines that are already licensed or currently in 
clinical testing. A common feature of many new adjuvants under development is that they 
stimulate pattern recognition receptors (PRRs) expressed by innate immune cells. Various 
families of PRRs are identified, including Toll-like receptors (TLRs), C-type lectin-like 
receptors (CLRs), nucleotide oligomerization domain (NOD) like receptors (NLRs), and 
retinoic acid-inducible gene-1 (RIG-1) like receptors (RLRs) (Awate et al., 2013). These 
receptors sense conserved microbial features collectively called pathogen associated 
molecular patterns (PAMPs), and initiate innate immune responses as well as set the stage 
for an efficient adaptive immune response (Medzhitov, 2007). The best characterised 
family of PRR is the TLR family and their ligands’ ability to induce inflammatory 
cytokines is explored for the immunostimulatory and adjuvant potential (Awate et al., 
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2013, Steinhagen et al., 2011, Coffman et al., 2010). 3-O-desacyl-4'-monofosforyl lipid A 
(MPL) is a detoxified derivative of lipopolysaccharide (LPS) and ligand for TLR4. MPL is 
part of Glaxo Smith Kline’s (GSK) Adjuvant System 04 (AS04) and is currently used in 
licensed vaccines against human papilloma virus and hepatitis B (Garçon et al., 2007). 
TLR ligands as potential vaccine adjuvants are covered in section 4.4.  
2.2. Adjuvants for fish vaccines 
The most common adjuvants in fish vaccines are based on mineral oil emulsions, which 
have been more or less unchanged since the development of these vaccines. These 
adjuvants increase immunogenicity of the antigen by making a depot at the injection site 
from which the antigen is slowly released (Tafalla et al., 2013). The emulsion usually 
consists of a water phase with the antigen dispersed in an oil phase (usually a mineral oil) 
with a surfactant (e.g. mannitol oleate) to stabilise the emulsion. The adjuvants registered 
under the trademark Montanide are based on mineral oil, non-mineral oil, or a mixture of 
both, and have been used in several commercialised fish vaccines. Freund’s complete 
(FCA) and incomplete (FIA) adjuvants (known from human adjuvant research) consist of 
surfactant and paraffin oil with or without heat-killed mycobacteria. Both have been tested 
in experimental fish vaccines with variable results, but have not yet been used in 
commercial vaccines (Tafalla et al., 2013).  
The side effects of oil-adjuvanted injection vaccines are undesirable for animal welfare 
reasons. Injectable vaccines formulated with oil-adjuvants can cause tissue lesions with 
granulomas at the injection site and abdominal cavity, adhesions between internal organs, 
autoimmunity reactions, reduced appetite and growth, and malfunction of reproductive 
organs (Koppang et al., 2004, Poppe and Breck, 1997, Håstein et al., 2005, Koppang et al., 
2005, Haugarvoll et al., 2010, Midtlyng and Lillehaug, 1998). In addition to the type of 
adjuvants used, water temperature, fish size, hygiene during handling, time of the year, and 
anaesthesia can also influence the development and severity of side-effects (Berg et al., 
2006, Håstein et al., 2005). 
Although lagging behind the human adjuvant research, there are also promising adjuvant 
candidates for fish vaccines currently under development. For example, biocompatible and 
biodegradable nano- and microparticles offer a promising alternative to oil emulsions. The 
antigen can be covalently bound to or physically entrapped in these particles. Formulations 
based on polymers like poly-(lactide-co-glycolide) (PLGA) and chitosan are tested as 
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adjuvant systems in several fish species, both in injectable and oral vaccines (Plant and 
LaPatra, 2011, Tafalla et al., 2013). Trough cloning studies and fish genome projects, 
increasing knowledge about the fish innate immune system and pathogen recognition (e.g. 
TLRs) have made it possible to move to adjuvants with more specific mechanisms of 
action. Compounds like beta-glucans, cytokines and different PAMPs (e.g. TLR ligands), 
alone or in combination, are now studied as possible adjuvant candidates in fish vaccines 
(Tafalla et al., 2013, Dalmo and Bøgwald, 2008, Thim et al., 2014, Thim et al., 2012, 
Carrington and Secombes, 2006, Fredriksen and Grip, 2012, Rivas-Aravena et al., 2015). 
TLR ligands as potential vaccine adjuvants are covered in section 4.4.  
3. Fish immune system  
Fish is the largest class of vertebrates and can be divided into jawless fish and jawed fish, 
and the latter can be further divided in to cartilaginous fish (e.g. sharks) and bony fish (e.g. 
teleosts) (Hitzfeld, 2005). Bony fish (Osteichthyes) possess most of the components in the 
immune system associated with the mammals. Teleosts are a branch of bony fish to which 
most of the economically important species belong (e.g. salmonid, carp, and tilapia 
species). Zebrafish (Danio rerio), a species important in research, also belongs to the 
teleosts. In contrast to higher vertebrates, fish are free-living organisms from early 
embryonic stages of life in which they depend on  their innate immune system for survival 
(Uribe et al., 2011).  
3.1. Fish immune organs and cells  
The immune organs of teleost fish differ from other vertebrates. Thymus, head kidney, and 
spleen are the main lymphoid organs in teleost, while bone marrow and lymph nodes are 
lacking. The head kidney (anterior part of the kidney) performs important immune function 
and is considered equivalent to the bone marrow in mammals. It also functions as a 
secondary lymphoid organ along with the spleen (Kaattari and Irwin, 1985, Kibenge et al., 
2012). Gut-associated lymphoid tissue (GALT) is well developed in teleosts (Salinas, 
2015), and a unique interbranchial lymphoid tissue (ILT) has been identified in salmonids 
(Koppang et al., 2010). 
Teleost fish possess most of the immune cells known from the mammalian immune 
system; neutrophils, monocytes/macrophages, eosinophils, non-specific cytotoxic cells 
(similar to mammalian natural killer cells), and T and B lymphocytes (Rauta et al., 2012, 
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Secombes, 1996, Whyte, 2007). Epithelial cells may also be involved in innate defence in 
fish (Whyte, 2007). Dendritic-like cells have also been found in some fish species and may 
together with macrophages and B cells act as antigen-presenting cells (Bassity and Clark, 
2012, Lugo-Villarino et al., 2010, Rauta et al., 2012). The main phagocytic cells in in fish 
are neutrophils and macrophages (Secombes and Fletcher, 1992). Respiratory burst and 
nitric oxide have been demonstrated in fish phagocytes (similar to homologous responses 
induced in mammalian phagocytes) and have been shown to be critical effector 
mechanisms in limiting the growth of fish pathogens (Neumann et al., 2001).  
3.2. Components of fish innate immune system  
The innate immunity is a fundamental defence mechanism in fish due to limitations of the 
adaptive immune system (Whyte, 2007). The physical barriers consist of skin, scales, and 
gills and represent the first line of defence against pathogens. The mucus covering the skin 
contains various components (e.g. lysozymes, IgM, antibacterial peptides, complement 
proteins, and lectins) which inhibit entry of pathogens (Uribe et al., 2011).  
Fish secrete a wide range of antimicrobial peptides (i.e. in the saliva, mucus, and 
circulatory system) that play major roles in the innate immune system and protect against a 
variety of pathogens (Rajanbabu and Chen, 2011). The complement system of fish seems 
to have all of the three complement activation pathways known from the mammalian 
system. Compared to other vertebrates, fish possess a number of genes encoding several 
complement components that are structurally and functionally diverse, indicating the 
importance of this system in a rapid response against invading pathogens (Plouffe et al., 
2005, Zhu et al., 2013) 
A number of TLRs have been identified in teleosts, and a more detailed description of 
mammalian and fish TLRs is presented in section 4. Other PPRs found in fish are RLR and 
NLR families. The three mammalian members of the RLR have been identified in several 
fish species (e.g. rainbow trout, Atlantic salmon, and zebrafish); RIG-1 (Biacchesi et al., 
2009, Nie et al., 2015), melanoma differentiation-associated gene 5 (MDA5) (also known 
as IFIH) (Sun et al., 2009, Chen et al., 2015, Chang et al., 2011a), and laboratory  of 
genetics and physiology 2 (LGP2) (Chang et al., 2011a, Chen et al., 2015). In mammals, 
RLRs are responsible for detection of cytoplasmic viral RNA and they appear to be 
involved in antiviral immune responses in fish as well (Kawai and Akira, 2008, Poynter et 
al., 2015). NLRs are also cytoplasmic receptors and sense bacterial cell wall components in 
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mammals (Kanneganti et al., 2007). They are also present in several fish species (e.g. 
rainbow trout and zebrafish) and are most likely involved in antibacterial and antiviral 
defences (Laing et al., 2008, Chang et al., 2011b, Zhu et al., 2013). In zebrafish, the 
intracellular peptide glycan (PGN) recognition proteins (PGRPs) have been identified and 
may work together with TLR2 in recognition of PGN from bacteria (Chang and Nie, 
2008). 
Cytokines are a family of low molecular weight proteins that are secreted from immune 
cells (e.g. macrophages and lymphocytes) upon pathogen encounter to modulate 
inflammation and cope with pathogen infection. They can be divided into interferons 
(IFNs), interleukins (ILs), tumor necrosis factors (TNFs), colony stimulating factors, and 
chemokines (Savan and Sakai, 2006). In general, fish possess a repertoire of cytokines 
similar to mammals (Reyes-Cerpa et al., 2012) and the most characterised ones in fish are 
the pro-inflammatory cytokines IL-1β and TNF-α (Plouffe et al., 2005). 
IL-1β is a pro-inflammatory cytokine, one of the first cytokines to be upregulated during 
an infection, and has been found in many fish species (Secombes et al., 2011). The fish IL-
1β share many of the characteristics with the mammalian counterpart, e.g. increases 
phagocytosis, chemotaxis, superoxide production, expression of important immune 
transcripts, leucocyte proliferation, and resistance to infection (Savan and Sakai, 2006, 
Plouffe et al., 2005, Hong et al., 2001, Peddie et al., 2001, Secombes et al., 2011). IL-1β 
activates target cells by binding to IL-1 receptors (IL-1R). Genes similar to the human IL-
1R gene have been identified in rainbow trout and Atlantic salmon and were upregulated 
during LPS treatment (Sangrador-Vegas et al., 2000, Subramaniam et al., 2002). TNF-α 
has also been identified in numerous fish species and differ from the mammalian 
counterpart in the presence of multiple isoforms in some species (e.g. zebrafish and 
rainbow trout) (Reyes-Cerpa et al., 2012). Expression of TNF-α has been shown to 
increase during LPS stimulation in several fish species (Plouffe et al., 2005). While 
recombinant trout TNF-α has been shown to induce increased migration and phagocytic 
activity in trout head kidney leukocytes (Zou et al., 2003), in several other fish species the 
in vitro effects of TNF-α were surprisingly weak (Reyes-Cerpa et al., 2012). IL-6 is 
another important pro-inflammatory cytokine in the early mammalian immune response 
against pathogens, but little is known about its functions in fish. IL-6 can be upregulated 
by mimics of infection and seems to have similar effects as IL-1β in rainbow trout and 
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zebrafish (Costa et al., 2011, Varela et al., 2012). However, IL-6 downregulated IL-1β and 
TNF-α in trout head kidney macrophages, suggesting a potential role in limiting host 
damage during inflammation (Costa et al., 2011). IL-10 is known to be anti-inflammatory 
in humans and the gene is associated with suppression of Th1 response (Brocker et al., 
2010). IL-10 has been identified in many fish species and while its role is not clear, it has 
been associated with mechanisms of immune evasion by IPNV in Atlantic salmon (Reyes-
Cerpa et al., 2014). Chemokines are chemotactic cytokines that are involved in recruiting 
immune cells to the infection site. The most studied fish chemokine is IL-8, which has 
shown chemo-attractant properties in rainbow trout (Omaima Harun et al., 2008) and has 
been tested as an adjuvant in a VHSV DNA vaccine (Jimenez et al., 2006).  
In mammals, interferons (IFNs) are the first line defence against viral infections. The large 
number of IFNs identified in vertebrates are grouped in type I (e.g. IFN-α and IFN-β), II 
(IFN-γ), and III (IFN-λ). Type I and III induce specific antiviral immune defences, while 
type II is involved in promoting cell-mediated immunity (Zou and Secombes, 2011). The 
nomenclature of fish IFNs has been controversial and several names and classifications 
exist. The type I IFN family of fish contains at least the four subtypes IFNa, IFNb, IFNc, 
and IFNd (Zou and Secombes, 2011). Atlantic salmon possess 11 virally induced IFN 
genes in a multiple gene cluster: two IFNa (IFNa1 and IFNa3), four IFNb (IFNb1–b4), and 
five IFNc (IFNc1–c5) (Sun et al., 2009). In addition, IFNa2 and IFNd has been found in 
Atlantic salmon, but outside the multiple gene cluster (Svingerud et al., 2012). Zebrafish 
also has an IFN gene cluster encoding IFNa1 (also called IFNϕ1/IFN1), IFNc1 and IFNc2 
(also called IFNϕ2/IFN2 and IFNϕ3/IFN3, respectively), but no IFNb. In addition, a 
zebrafish IFNd1 (also called IFNϕ4) has been identified (Zou and Secombes, 2011, 
Hamming et al., 2011). Fish also possess homologues of mammalian type IIs (IFNγ) and 
these might be involved in both antiviral and –bacterial responses (Zou and Secombes, 
2011). IFN expression is modulated by a family of transcription factors called interferon-
regulatory factors (IRFs) which has been shown to exist in all vertebrates (Zhu et al., 
2013). Type I IFNs work through IFN receptors to activate the Jak-Stat signalling pathway, 
of which all components have been identified in fish (Zhang and Gui, 2012, Levraud et al., 
2007, Sun et al., 2014). This signalling pathway leads to expression of IFN-stimulated 
genes (ISGs) that exert numerous antiviral effector functions (Schoggins and Rice, 2011). 
Multiple ISGs have been identified in fish (e.g. ISG15 and Mx) that have shown to be 
virus-induced and exert antiviral activity in several fish species (Altmann et al., 2004, 
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Robertsen et al., 1997, Røkenes et al., 2007, Langevin et al., 2013, Jensen et al., 2002, 
Zhang and Gui, 2012). Furthermore, members of the ISG protein family IFIT (interferon-
induced proteins with tetratricopeptide repeats) have shown antiviral function in zebrafish 
(Varela et al., 2014). 
3.3. Brief overview of adaptive immunity in fish  
The adaptive immunity can be divided into cell-mediated and humoral immunity. Fish 
seem to have lymphocyte subpopulations similar to the mammalian B and T cells and 
possess many important genes related to an adaptive immune response: MHC class I and 
II, T-cell receptor, CD4, CD8, and immunoglobulins. The presence of cytotoxic T cells 
(CD8+ cells) has been suggested (Nakanishi et al., 2011). Moreover, cytokines that in 
mammals are considered signature cytokines for Th1, Th2, and Th17 responses, have been 
identified in fish, and thus suggest the presence of Th1, Th2, and Th17 cells (Laing and 
Hansen, 2011). The main immunoglobulin in teleost is IgM, which has a heavy chain 
similar to the mammalian B cells. Fish IgM has a tetrameric structure (as opposed to the 
mammalian IgM pentameric structure) and is the primary antibody in fish serum (Solem 
and Stenvik, 2006). Additional immunoglobulin isotypes have also been identified in fish: 
IgD and IgT/IgZ (called IgT in rainbow trout (Hansen et al., 2005) and IgZ in zebrafish 
(Danilova et al., 2005)). IgT may be important in the GALT of rainbow trout, thus perhaps 
representing a functional analogue to IgA (Zhang et al., 2010). The existence of B cells 
with phagocytic and bactericidal activity has been suggested (Sunyer, 2012). Isotype 
switch has not been described in fish and the antibody response is generally known for 
being slow, having low affinity, and being temperature dependent (Sunyer, 2012). 
However, there are several examples showing that fish are able to induce specific and 
strong antibody responses after pathogen challenge or vaccination, and that antibody levels 
can be used as a correlate of protection (Munang’andu et al., 2013, Solem and Stenvik, 
2006, Fjalestad et al., 1996, Steine et al., 2001, Thim et al., 2012).  
4. Toll-like receptors (TLRs) 
4.1. Mammalian TLRs and their ligands 
In human vaccinology, the TLRs and their ligands have been extensively studied. TLRs 
are, as previously mentioned, important receptors that sense invading pathogens (O'Neill et 
al., 2013). TLRs appeared in the early stages of evolution and have been conserved in both 
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invertebrate and vertebrate lineages (Medzhitov and Janeway, 2000). The first evidence of 
the Toll NF-κB-like signalling pathway was discovered when the Toll protein was found to 
be required for fungal resistance in fruit flies (Drosophila melanogaster) (Lemaitre et al., 
1996) and a short time later the human homolog of Toll was found (Medzhitov et al., 
1997). Since then, TLRs have been described in a wide variety of vertebrate species. Six 
major TLR families (TLR1, TLR3, TLR4, TLR5, TLR7, and TLR11) have been identified, 
and TLRs within a family recognise a general class of PAMPs associated with the family 
(Roach et al., 2005). TLRs are transmembrane proteins containing an extracellular 
recognition domain composed of multiple leucine-rich region (LRR) motifs, a 
transmembrane region, and an intracellular Toll/interleukin-1 receptor (TIR) signalling 
domain (named TIR because the similarity of the IL-1R signalling domains) (Botos et al.). 
Upon binding a ligand, the TLRs are relocated into the lipid raft fraction of the cell 
membrane (Sadikot, 2012) before two TLRs dimerise (either heterodimerisation or 
homodimerisation) for firm ligand binding (Jin and Lee, 2008). The close proximity of the 
TIR domains of paired TLRs allows recruiting of TIR domain-containing adaptor proteins. 
These adaptors are Myeloid differentiation primary response gene (88) (MyD88), Mydd88-
adaptor-like (MAL, also known as TIRAP), TIR-domain-containing adaptor protein 
inducing IFN-β (TRIF, also known as TICAM1), TRIF-related adaptor molecule (TRAM, 
also known as TICAM2), or sterile α-and armadillo-motif-containing protein (SARM) 
(O'Neill and Bowie, 2007). The engagement of the adaptor molecules stimulates 
downstream intracellular signalling pathways. These pathways involve interactions 
between IL-1R-associated kinases (IRAKs) and TNF-receptor-associated factors (TRAFs) 
and will eventually lead to activation of transcription factors (nuclear factor kappa B (NF-
κB), interferon regulatory factors (IRFs), cyclic AMP-responsive element-binding protein 
(CREB), or activator protein 1 (AP1)) that control hundreds of different immune-relevant 
genes. The intracellular signalling cascade is complex and several other factors are 
involved; however, not all of them can be described in detail here. The adaptor molecules 
involved, the signalling pathway induced, and the cytokine expression profile following 
stimulation of a TLR, depend on the type of pathogen and the TLRs recognising the 
pathogen, as shown in Figure 2 (O'Neill et al., 2013). The transcription factors activated 
lead to upregulation of pro-inflammatory cytokines (e.g. IL-β, TNF-α, and IL-6) involved 
in inflammation and/or Type I IFNs (IFN-α, IFN-β) involved in antiviral immune response 
(see Figure 2). 
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Figure 2: Overview of mammalian TLR signalling pathways. Figure from (O'Neill et al., 2013). 
 
The diversity of the LRR folding defines the TLR binding specificities and will orchestrate 
the appropriate innate and adaptive immune responses against the specific pathogen. 
TLR1, TLR2, TLR4, TLR5, and TLR6 are localised on the cell surface (TLR4 can also be 
found in endosomes) and recognise cell wall PAMPs, while TLR3, TLR7, TLR8, and 
TLR9 are localised in membranes of intracellular compartments (like endosomes) and 
recognise nucleic acids. Bacterial PAMPs are mainly sensed by TLR1, TLR2, TLR4, 
TLR5, TLR6, and TLR9, while viral PAMPs are sensed by TLR3, TLR7, TLR8, and 
TLR9 (Jin and Lee, 2008, Werling et al., 2009). An overview of mammalian TLRs and 
their ligands is presented in Table 2.  
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Table 2: Mammalian TLRs and their ligands 
TLR Species Localisation Ligand examples  
TLR1/TLR2 Human 
Mouse 
Plasma membrane Bacterial triacylated lipopeptides 
Mycobacterial products 
Porins 
Synthetic triacylated lipopeptides  
(e.g. Pam3CSK4) 
TLR2/? Human 
Mouse 
Plasma membrane Bacterial lipoproteins 
Staphylococcus peptidoglycan 
Viral proteins (from certain viruses) 
TLR3 Human 
Mouse 
Endosomal membrane Viral double stranded RNA 
PolyI:C 
TLR4 
(+ MD-2 and 
CD14) 
Human 
Mouse 
Plasma and  
endosomal membrane 
Lipopolysaccharide (LPS) 
Lipid A derivatives (e.g. monophosphoryl A (MPL)) 
Viral proteins (from certain viruses) 
TLR5 Human 
Mouse 
Plasma membrane Bacterial flagellin 
Recombinant flagellin 
TLR2/TLR6 Human 
Mouse 
Plasma membrane Bacterial diacylated lipopeptides 
Lipoteichoic acid 
Synthetic diacylated lipopeptides (e.g. FSL-1, Pam2CSK4)) 
Zymosan 
TLR7 Human 
Mouse 
Endosomal membrane Viral and bacterial single stranded RNA 
Thiazoquinolines 
Imidazoquinolines (e.g. imiquimod) 
TLR8 Human 
Mouse 
Endosomal membrane Viral and bacterial single stranded RNA 
Thiazoquinolines 
Imidazoquinolines (e.g. resiquimod) 
TLR9 Human 
Mouse 
Endosomal membrane Viral and bacterial CpG DNA 
DNA:RNA hybrids 
Class A, B and C CpG oligodeoxynucleotides (e.g.ODN2006) 
TLR10 Human Plasma membrane Unknown 
TLR11 Mouse Endosomal membrane Profilin, flagellin 
TLR12 Mouse Endosomal membrane Profilin 
TLR13 Mouse Endosomal membrane Bacterial ribosomal RNA, vesicular stomatitis virus  
References (De Nardo, 2015, Oliviera-Nascimento et al., 2012, Bowie and Haga, 2005, Shi et al., 2011) 
 
Mammalian TLR2 requires heterodimerisation with TLR1 or TLR6 and is involved in 
recognition of bacterial and fungal cell wall components. Homodimerisation of TLR2 has 
been suggested, but not confirmed (Oliviera-Nascimento et al., 2012). Several synthetic 
compounds that mimic bacterial lipoproteins (e.g. Pam3CSK3 and FSL-1) are well 
established agonists for mammalian TLR1/2 and TLR2/6 (Okusawa et al., 2004, Aliprantis 
et al., 1999, Ozinsky et al., 2000). TLR4 recognises Gram-negative bacteria via the lipid A 
part of LPS (Poltorak et al., 1998). The recognition of LPS also requires the co-receptors 
MD-2 and CD14, and the LPS-binding protein (LBP) facilitates the transfer of LPS to 
CD14 (Park and Lee, 2013). TLR4 is unique in being able to signal trough both 
Myd88/MAL and TRIF/TRAM. It uses the adaptor TRAM to recruit TRIF and induce 
IRF3 activation and IFN-β expression, but can also use MAL to recruit Myd88, which 
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leads to activation of NF-κB and AP-1 that will induce pro-inflammatory cytokines 
(Thompson and Locarnini, 2007). In addition, TLR2 and TLR4 have been shown to 
interact with viral components (e.g. viral glycoproteins) and may participate in in viral 
detection (Bowie and Haga, 2005). 
TLR3 is responsible for sensing viral double-stranded RNA (dsRNA) (Alexopoulou et al., 
2001) and is the only TLR that works via the Myd88-independent pathway. The adaptor 
TRIF is instead essential for TLR3-mediated signalling. TRIF interacts with TRAF3 to 
activate a kinase cascade that leads to the activation of IRF3, which induces expression of 
IFN-β. TRIF can also interact with TRAF6 to induce a late phase NF-κB and pro-
inflammatory cytokine response (Thompson and Locarnini, 2007, Jensen and Thomsen, 
2012). Polyinosine–polycytidylic acid (poly I:C) is a synthetic analogue of dsRNA that 
binds TLR3 and is extensively used to mimic a viral infection (Fortier et al., 2004). The 
natural ligand for human TLR7 and TLR8 is single-stranded RNA (ssRNA) (Heil et al., 
2004, Lund et al., 2004). In addition, a group of synthetic antiviral-RNA-like compounds 
(e.g. imiquimod) work by binding TLR7 and TLR8 (Hemmi et al., 2002, Lee et al., 2003a). 
Human TLR9 recognises bacterial and viral DNA, which typically contain un-methylated 
CpG oligodeoxynucleotides (ODNs) in higher frequencies than human DNA (Hemmi et 
al., 2000). TLR7, TLR8, and TLR9 signal trough Myd88 and TRAF6 that lead to 
activation of both NF-κB to upregulate pro-inflammatory cytokines and IRF7 to upregulate 
IFN-α and IFN-β (Thompson and Locarnini, 2007, Jensen and Thomsen, 2012). 
4.2. TLRs in fish 
The advances in fish genomic research during the last decade have led to the discovery of 
TLR genes in many species of bony fish. Ever since the first teleost TLR was discovered in 
goldfish macrophages (Stafford et al., 2003), about 20 TLR types (TLR1, 2, 3, 4, 5M, 5S, 
7, 8, 9, 13, 14, 18, 19, 20, 21, 22, 23, 24, 25, and 26) have been identified in more than a 
dozen of teleost species (Rauta et al., 2014). The fish TLRs and the factors involved in 
their signalling cascade have high structural similarity to the mammalian TLR system. 
Figure 3 shows a phylogenetic tree comparing full-length TLR amino acids sequences 
from Atlantic salmon, rainbow trout, and zebrafish with the human and mice TLRs. The 
tree shows the homology of the different TLRs between the different species, and that the 
TLRs make up six TLR families. Most vertebrate genomes are actually found to have at 
least one gene representing each of the six major TLR families (Roach et al., 2005). 
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Although fish TLRs have high structural similarity with mammalian TLRs and possess 
many homologues of the mammalian TLRs, they also have distinct features and 
differences. Some mammalian TLRs have yet to be found in fish and several non-
mammalian and fish-specific TLRs have been identified (Palti, 2011). In many fish species 
(e.g. Atlantic salmon and rainbow trout), a soluble form of TLR5 (TLR5S) has been 
identified in addition to the membrane-bound form (TLR5M). Two putative soluble forms 
of TLR20 have also been found in Atlantic salmon (Lee et al., 2014). Other non-
mammalian TLR genes found in several fish species are TLR14 and TLR18 that branches 
with the TLR1 family, and TLR19-26 that belongs to the TLR11 family alongside mouse 
TLR11-13 (see Figure 3). Some of these TLRs are unique to fish (e.g. TLR22), while 
others have only been found in aquatic animals (e.g. TLR14) (Rauta et al., 2014). 
Orthologues of TLR6 and TLR10 seem to be absent from fish genomes, but TLR14 and 
TLR18 have been proposed as possible substitutes (Zhang et al., 2014). Zebrafish is one of 
the few fish species in which TLR4 has been identified (Meijer et al., 2004, Jault et al., 
2004). Fish TLR21 has shown similarity to chicken TLR21, which is considered a 
functional homologue to mammalian TLR9 (Brownlie et al., 2009). Genome- and gene 
duplication events have been contributors to the diversity of the TLRs in fish and a number 
of duplicate multi-copy TLRs have been identified (e.g. Atlantic salmon TLR8a1, TLR8a2, 
TLR8b1, and TLR8b2) (Palti, 2011).  
Unc93B1 is a chaperone that appears to be important for the trafficking of endosomal 
TLRs (TLR3, TLR7, TLR8, TLR9, and TLR11-13) within the mammalian cell (Gay et al., 
2014). The gene has been identified in Atlantic salmon and zebrafish, and is thought to 
have a role in fish TLR signalling (Yeh et al., 2013, Lee et al., 2015). Most of the 
downstream molecules involved in TLR signalling have also been identified in fish and the 
pathways seem to be conserved. However, information on the functional importance of 
many of these genes is lacking (Rebl et al., 2010, Kanwal et al., 2014). Myd88 has been 
identified in Atlantic salmon, rainbow trout, and zebrafish, and seems to function similarly 
to the mammalian counterpart (Skjæveland et al., 2009, van der Sar et al., 2006, Iliev et al., 
2011, Rebl et al., 2009). Furthermore, MAL, TRIF, IRAK4, TRAF6, NF-κB, IRF3, and 
IRF7 have also been identified in fish (Phelan et al., 2005, Brietzke et al., 2014, Iliev et al., 
2011, Meijer et al., 2004, Kanwal et al., 2014, Purcell et al., 2006); but TRAM has not 
been identified in any fish to date (Zhang et al., 2014).  
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Figure 3: Circular phylogenetic tree of full-length TLR amino acid sequences of Atlantic salmon 
(Salmo salar, Ss), Rainbow trout (Oncorhynchus mykiss, Om), Zebrafish (Danio rerio, Dr), human 
(Homo sapiens, Hs) and mouse (Mus musculus, Mm). Bootstrap values based on 100 replicates are 
indicated on each branch. Accession numbers of sequences used to build the three are as follows: 
Danio rerio (TLR1: AAI63271, TLR2: NP_997977, TLR3: NP_001013287, TLR4ba: 
NP_001124523, TLR4bb: NP_997978, TLR5a: XP_001919052, TLR5b: NP_001124067, TLR7: 
XP_003199309, TLR8a: XP_001920594, TLR8b: XP_003199440, TLR9: NP_001124066, TLR18: 
AAI63840, TLR19: AAQ91317, TLR20a: AAI63786, TLR20f: AAQ91319, TLR21: NP_001186264, 
TLR22: NP_001122147); Homo sapiens (TLR1: NP_003254, TLR2: NP_003255, TLR3: 
NP_003256, TLR4: NP_612564, TLR5: NP_003259, TLR6: NP_006059, TLR7: NP_057646, 
TLR8: NP_619542, TLR9: NP_059138, TLR10: NP_001017388); Mus musculus (TLR1: 
NP_109607, TLR2: NP_036035, TLR3: NP_569054, TLR4: NP_067272, TLR5: NP_058624, 
TLR6: NP_035734, TLR7: NP_573474, TLR8: NP_573475, TLR9: NP_112455, TLR11: 
NP_991388, TLR12: NP_991392, TLR13: NP_991389); Oncorhynchus mykiss (TLR1: 
NP_001159573, TLR2: CCK73195, TLR3: NP_001118050, TLR5S: NP_001118216, TLR5S: 
P_001117680, TLR7: ACV41797, TLR8a1: ACV41799, TLR8a2: ACV41798, TLR9: ACC93939, 
TLR19: CCW43211, TLR22a1: NP_001117884, TLR22a2: CAI48084);  Salmo salar (TLR1: 
AEE38252, TLR3: AKE14222, TLR5M: AEE38253, TLR5S: AEE38254, TLR7: CCX35457, 
TLR8a1: NP_001155165, TLR8a2: CCX35458, TLR8b1: CCX35459, TLR8b2: CCX35460, TLR9: 
ABV59002, TLR13: NP_001133860, TLR18: CDK60413, TLR19: CDH93609, TLR20a: 
CDH93610, TLR20d: CDH93613, TLR21: CDH93614, TLR22a: CAJ80696, TLR22a2: 
CAR62394).Figure made by M.Arnemo with CLC Main Workbench7. 
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4.3. Ligand specificity of fish TLRs  
Many functional studies have failed to detect ligand specificities for fish TLRs.  Direct 
ligand specificity has only been reported for a few TLRs, using in vitro reporter assays to 
detect ligand recognition (Ribeiro et al., 2010, Matsuo et al., 2008, Tsujita et al., 2004, Yeh 
et al., 2013). However, numerous published stimulation and gene expression analyses 
discuss possible ligand specificities and roles of fish TLRs during infection. The studies 
concerning Atlantic salmon, rainbow trout, and zebrafish will be reviewed here.  
Since TLR6 has yet to be found in most fish genomes, TLR1 is the most likely partner for 
heterodimerisation with TLR2 in fish (Pietretti and Wiegertjes, 2013). Few reports are 
available on salmonid TLR1 and TLR2, but bacterial infection has shown to upregulate 
TLR1 in vitro (Salazar et al., 2015), while Pam2CSK4 and Pam3CSK4 (classical ligands 
for human TLR2/6 and TLR1/2, respectively) seemed to have a lower potential for 
inducing TLR and cytokine expression (Palti et al., 2010b, Purcell et al., 2006). Zebrafish 
TLR18 branches with the TLR1 family and was upregulated together with TLR1 and 
TLR2 during M.marinum infection (Meijer et al., 2004). Atlantic salmon, rainbow trout, 
and zebrafish TLR3 have been cloned and characterised by expression analysis, which 
demonstrated upregulation of TLR3 and type I IFNs following infection with aquatic 
viruses or poly I:C stimulation (Phelan et al., 2005, Vidal et al., 2015, Svingerud et al., 
2012, Purcell et al., 2006, Rodriguez et al., 2005, Jensen et al., 2002, Dios et al., 2010). 
This indicates conservation of TLR3-signalling pathways as well as involvement in 
antiviral immunity and binding of dsRNA.  
The high tolerance of LPS in fish was for a long time explained by the lack of TLR4 in 
most fish genomes (e.g. Atlantic salmon and rainbow trout). This explanation was 
challenged when two TLR4 genes (TLR4ba and TLR4bb) were identified in zebrafish 
(Meijer et al., 2004, Jault et al., 2004). However, the apparent absence of CD14, MD-2, 
and LBP from all fish genomes may play a role (Pietretti and Wiegertjes, 2013). Although 
zebrafish tolerate high doses of LPS, LPS has been shown to exert multiple biological 
effects (Novoa et al., 2009, Swain et al., 2008). It seems that zebrafish are responsive to 
LPS through a TLR4-independent pathway, thus suggesting an alternative LPS induction 
pathway in fish (Sullivan et al., 2009, Sepulcre et al., 2009). Aedo et al. (2015) proposed 
that TLR5M and TLR9 may play a role in detecting LPS in rainbow trout (Aedo et al., 
2015). Conservation of flagellin binding by TLR5 has been suggested in rainbow trout, 
Introduction
 
 
34 
 
Atlantic salmon, and zebrafish. Both forms of rainbow trout TLR5 (soluble and membrane-
bound), in a chimeric form with TIR domain from human TLR5, stimulated NF-κB 
activation in vitro after exposure to flagellin (Tsujita et al., 2004). Flagellin has also been 
shown to induce upregulation of pro-inflammatory cytokines and both TLR5 forms in vitro 
and in vivo in salmonids (Hynes et al., 2011, Purcell et al., 2006, González-Stegmaier et 
al., 2015). In zebrafish, the two TLR5 isoforms (TLR5a and TLR5b) were upregulated in 
several studies during bacterial infections and flagellin stimulation (Meijer et al., 2004, 
Stockhammer et al., 2009, van der Sar et al., 2009, Yang et al., 2013). Additionally, 
morpholino-induced TLR5 zebrafish knockdowns led to a reduction of flagellin-induced 
inflammation (Yang et al., 2015).  
Upregulation of type I interferons and pro-inflammatory cytokines have been demonstrated 
by stimulation with TLR7 and TLR8 ligands in rainbow trout (in vitro) and Atlantic 
salmon (in vitro and in vivo) (Purcell et al., 2006, Kileng et al., 2008, Palti et al., 2010a, 
Svingerud et al., 2012). Type I interferons upregulated TLR7 and TLR8 variants in 
Atlantic salmon (Lee et al., 2013), while in vivo viral infections both induced or not 
affected TLR8 expression (Skjæveland et al., 2009, Skjesol et al., 2011). Stimulation by 
CpG ODNs has been studied a lot in salmonids, both in vivo and in vitro. CpG ODNs have 
been shown to both upregulate and not affect TLR9 expression (Ortega-Villaizan et al., 
2009, Skjæveland et al., 2008, Strandskog et al., 2008), while pro-inflammatory cytokines, 
type I IFN, and ISGs  usually are upregulated by these PAMPs (Strandskog et al., 2008, 
Jørgensen et al., 2001, Jørgensen et al., 2003, Carrington and Secombes, 2006). Bacterial 
infections have been shown to induce zebrafish TLR9 expression (Meijer et al., 2004, Uma 
et al., 2012) and TLR9 has been demonstrated to recognise CpG ODNs in a NF-κB-
reporter assay (Yeh et al., 2013). 
The non-mammalian TLRs have also been investigated in several infection and stimulation 
studies. It has been proposed that TLR3 may not be the only TLR that senses viral dsRNA 
in fish, as fugu TLR22 was demonstrated to recognise long-sized dsRNA when tested for 
IFN-β activation in an in vitro reporter assay (Matsuo et al., 2008). Binding of dsRNA has 
also been suggested for zebrafish TLR22 (Sahoo et al., 2014). Bacterial infections have 
been shown to upregulate TLR22 in rainbow trout and zebrafish (Meijer et al., 2004, Rebl 
et al., 2007). In addition, poly I:C, PGN, and LPS have been shown to upregulate zebrafish 
TLR22 (Sundaram et al., 2012). In the same study, these TLR ligands also upregulated 
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zebrafish TLR21, which later was shown to recognise CpG ODNs in a NF-κB-reporter 
assay (Yeh et al., 2013). TLR20 has been suggested a role in immune response to 
protozoan parasites in fish, similar to the murine TLR11 and TLR12 (Pietretti et al., 2014, 
Zhang et al., 2014). However, Atlantic salmon TLR18-21 were mostly unaffected or 
downregulated during ISAV infection (Lee et al., 2014), thus the functional role of many 
of these TLRs is not yet clear. 
4.4. TLR ligands as vaccine adjuvants 
Due to the TLR ligands’ ability to induce inflammatory cytokines and important immune 
mediators, these ligands are extensively explored for their adjuvant properties in human 
vaccines, and the list of TLR ligands in clinical trials is long (Toussi and Massari, 2014, 
Steinhagen et al., 2011, Tomai and Vasilakos, 2012). With more knowledge about the 
existence of fish TLRs, research on these ligands in fish vaccinology is also increasing 
(Tafalla et al., 2013). 
The TLR4 ligand LPS and its derivatives are the most widely tested TLR ligands in human 
vaccines. Due to LPS toxicity, its use in human vaccines was limited until detoxified 
variants were developed. The TLR4 agonist MPL, a low-toxicity derivative of LPS, is a 
component that together with aluminium hydroxide is included in the GSK adjuvant AS04. 
Aluminium salt adjuvants are known for inducing Th2-dominating immune responses, but 
when combined with MPL, Th1 responses are induced. This makes AS04 especially useful 
for vaccines against intracellular pathogens (Duthie et al., 2011, Didierlaurent et al., 2009). 
Poly I:C and CpG ODNs, ligands for TLR3 and TLR9, respectively, have proven effective 
as vaccine adjuvants in clinical trials. Because of poly I:C’s potent antiviral activity and 
mimicking of viral infection, there are numerous studies on its immunostimulatory 
potential in therapeutics or vaccines available (Hafner et al., 2013). Similar to other 
dsRNA complexes, poly I:C leads to induction of IL-12 and type I IFN, and it can promote 
Th1 based immunity, development of CD8+ T cells, and enhance antibody production 
against several viral antigens (e.g. influenza, HIV, and hepatitis B) (Toussi and Massari, 
2014, Tomai and Vasilakos, 2012). Lipopeptides (e.g. Pam3CKS) and flagellin have also 
reached clinical trials, but most of the knowledge about these ligands results from pre-
clinical models. Their effect is characterised predominantly as Th2-biased and are typically 
tested out in bacterial vaccines. Agonists for TLR7 and TLR8, are less developed as 
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vaccine adjuvants, but are in use in topical formulations in antiviral and cancer 
immunotherapy (Toussi and Massari, 2014). 
As reviewed in section 4.3., several TLR ligands seem to have immunostimulatory 
properties in fish. The non-specific antiviral effect has been tested for several TLR ligands 
in fish. For example, poly I:C and CpG have been shown to induce an antiviral state strong 
enough to confer resistance to viral challenge in several fish species (Ruyra et al., 2014, 
Jørgensen et al., 2003, Jensen et al., 2002, Kim et al., 2009, Nishizawa et al., 2009, Oh et 
al., 2012, Takami et al., 2010). Although several studies focus on the non-specific 
immunostimulatory properties of these ligands, there are few reports available on the 
adjuvant effect together with an antigen (Tafalla et al., 2013, Carrington and Secombes, 
2006). However, the combination of poly I:C and CpG as adjuvant in an inactivated SAV 
vaccine have shown promising results as adjuvant strategy (Thim et al., 2012, Thim et al., 
2014, Strandskog et al., 2008).  
5. Dietary n-3 fatty acids and immune responses 
Fish oil is the major source of the very long-chain n-3 polyunsaturated fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Due to increasing demand 
for EPA and DHA as ingredients in human health products and fish feed, there is now a 
shortage of these fatty acids on the international markets. This has led to increased 
substitution of fish oil by plant oils in Atlantic salmon feed (Figure 4), thereby reducing the 
EPA and DHA content of salmon.  
EPA and DHA are well known to modulate inflammation and immune responses in 
humans and experimental animals, and their main effects are generally recognised to be 
anti-inflammatory (Hummell, 1993, Calder, 2013). The composition of fatty acids in 
membrane phospholipids of mammalian immune cells strongly correlate with the profile of 
dietary lipids (Calder, 2013). EPA and DHA have been suggested to modulate TLR 
function trough interfering with lipid rafts and signalling platforms in the cell membrane of 
mammalian immune cells (Calder, 2013, Lee et al., 2003b, Norris and Dennis, 2012). 
Also in fish, varying the dietary levels of EPA and DHA has been shown to alter the fatty 
acid composition in organs rich in immune cells like the head kidney (Bell et al., 1993, 
Hvattum et al., 2000, Ganga et al., 2005, Bell et al., 1998). Since membrane phospholipids 
are a part of the microenvironment for leucocyte transmembrane signalling receptors (e.g. 
Introduction
 
 
37 
 
TLRs), the effects of dietary EPA and DHA may have consequences for leucocyte function 
and fish health (e.g. clearance of pathogens and vaccine effects).  
 
Figure 4: Nutrient sources in Norwegian salmon farming from 1990 to 2013. Each ingredient type 
is shown as its percentage of the total diet. In 2013, only 30% of the ingredients were of marine 
origin compared to 90% in 1990. Figure from (Ytrestøyl et al., 2015). 
 
Investigations of the effects of low n-3 fatty acid in diet or cell media have demonstrated 
varying results on immune cell function and diseases resistance in fish (Montero and 
Izquierdo, 2010). The replacement of fish oil by vegetable oil has demonstrated to impair 
macrophage function (e.g. phagocytosis and respiratory burst) in several studies (Kiron et 
al., 1995, Montero et al., 2003, Montero et al., 2008, Sheldon and Blazer, 1991). On the 
contrary, other papers reported no effects on immune cell function of this replacement 
(Seierstad et al., 2009, Gjøen et al., 2004). Regarding disease resistance in vivo, both 
decreased, increased and no effects on mortality have been demonstrated in fish 
(Thompson et al., 1996, Waagbø, 1994, Gjøen et al., 2004, Lødemel et al., 2001, Bransden 
et al., 2003). Dietary lipids can obviously affect immune functions in fish, however, it the 
role of these lipids on fish health is not clear. In addition, little is known about the 
molecular mechanisms.  
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Aims of the thesis 
In human vaccinology, the TLRs are studied in great detail and their ligands are explored 
for their adjuvant and immunostimulatory properties. This research has led to several new, 
efficient adjuvants. There is a need for new adjuvants in fish vaccines. To benefit what is 
known from human adjuvant research, a greater molecular understanding and functional 
description of the similarities and differences between mammalian and fish innate 
immunity is needed. Therefore, increased knowledge of fish TLR function is required 
before their ligands can be used in fish vaccines as adjuvants. 
Main objective: 
Contribute to a more detailed understanding of fish TLRs.  
Sub-objectives: 
1. Provide an overview over TLR expression and function in Atlantic salmon by 
investigating tissue distribution of TLRs, the impact of viral infection on TLR 
expression, and the cytokine induction potential of TLR ligands in primary 
leucocytes. 
2. Functionally validate ligand-specific activation of fish TLRs by using an in vitro 
reporter assay. 
3. Test the in vivo immunostimulatory potential of a TLR ligand in zebrafish. 
4. Test the adjuvant effects of a TLR ligand in virus vaccines in vivo in zebrafish. 
5. Investigate if various dietary levels of EPA and DHA can affect TLR signalling in 
Atlantic salmon.  
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Summary of papers 
Paper I: Effects of TLR agonists and viral infection on cytokine and TLR expression 
in Atlantic salmon (Salmo salar).  
Arnemo M, Kavaliauskis A, Gjøen T.  
Developmental and Comparative Immunology (2014) 
To provide an overview of TLR expression and function in Atlantic salmon, we used 
primers of all known Atlantic salmon TLRs at the time to investigate tissue distribution of 
TLRs, the immunostimulatory potential of classical TLR ligands in primary leucocytes (in 
vitro), and the impact of viral infection on TLR expression (in vivo). Head kidney and 
spleen were the main organs expressing TLRs in Atlantic salmon. Adherent head kidney 
leucocytes were isolated and stimulated with a panel of known ligands for human TLR1-9. 
The cells were able to respond to many of the ligands in terms of upregulating pro-
inflammatory cytokines, IFNs, and Mx. Poly I:C and imiquimod induced expression of 
IFNs and Mx, which are important in antiviral immunity. TLR3, TLR7, and TLR8a1 were 
upregulated in head kidney of ISAV infected fish.  
Paper II: Structurally diverse genes encode TLR2 in rainbow trout: The conserved 
receptor cannot be stimulated by classical ligands to activate NF-kappaB in vitro. 
Brietzke A, Arnemo M, Gjøen T, Rebl H, Korytář T, Goldammer T, Rebl A, Seyfert HM. 
Developmental and Comparative Immunology (2016)  
We wanted to establish a functional assay to screen for fish TLR ligand specificity. The 
mammalian TLR2 is important in recognition of bacterial cell wall components, but has 
also been demonstrated to sense certain viral proteins. Alexander Rebl and his group 
obtained the full-length cDNA sequence encoding TLR2 from rainbow trout 
(Oncorhynchus mykiss, Om). The primary structure of the encoded receptor complied with 
the domain structure and ligand-binding sites known from mammals and other fish species. 
OmTLR2a was expressed both in HEK-293 and salmon CHSE-214 cells together with an 
NF-kB luciferase reporter plasmid. Regarding the CHSE-214 cell assay, we first validated 
that poly I:C and flagellin, but not FSL-1 or Pam3CSK4 stimulation activated NF-kB in 
these cells. However, no significant ligand-dependent activation of NF-kB could be 
detected in TLR2a-transfected CHSE-214. Neither synthetic lipopeptides known to 
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stimulate mammalian TLR2, nor exposure to different bacteria induced OmTLR2-
mediated activation. 
Paper III: Use of poly I:C stabilised with chitosan as a vaccine-adjuvant against Viral 
Haemorrhagic Septicaemia Virus infection in zebrafish.  
Kavaliauskis A, Arnemo M, Kim SH, Ulanova L, Speth M, Novoa B, Dios S, Evensen Ø, 
Griffiths GW, Gjøen T.  
Zebrafish (2015). 
There is a need for new adjuvants and more efficient viral vaccines in fish farming. By 
using zebrafish as a model system, we could test the in vivo immunostimulatory and 
antiviral resistance properties of poly I:C. In addition, the adjuvant effect of poly I:C 
stabilised with chitosan could be tested in an inactivated VHSV vaccine. Poly I:C proved 
to be a strong inducer of the antiviral state, measured by transcriptional activation of the 
genes of viral sensors and effectors (TLRs, IFNs, and ISGs), and delayed VHSV-induced 
mortality when injected 24 hours pre-challenge. Poly I:C was stabilised with chitosan and 
co-injected with inactivated VHSV (CSpIC+iV vaccine) in adult zebrafish. The protective 
effect against VHSV was compared to a live attenuated VHSV vaccine (aV). Both 
CSpIC+iV and aV formulations provided protection against VHSV-induced mortality. 
However, when plasma from survivors was tested for neutralizing antibodies in an in vitro 
protection assay, we could not demonstrate any protective effect. Plasma from aV 
vaccinated fish enhanced cytopathic effects, indicating that antibody-dependent entry may 
play a role in this system. 
Paper IV: Chitosan-poly I:C nanoparticles: a novel adjuvant in aquaculture vaccines. 
A study of particle bio- distribution and immune response in zebrafish (Danio rerio). 
Kavaliauskis A, Arnemo M, Speth MT, Lagos Rojas LX, Rishovd AL, Estepa A, Griffiths 
G, Gjøen T.  
Manuscript submitted for publication. 
To further test the adjuvant effects of poly I:C, we made a subunit vaccine consisting of the 
recombinant VHSV glycoprotein G (rgpG). The protective effect of the rgpG compared to 
inactivated whole virus (iV) using chitosan-poly I:C nanoparticles as adjuvant was studied 
in zebrafish. Formulations containing free poly I:C + rgpG (pICrgpG) and free chitosan + 
rgpG (CSrgpG) were also compared. All vaccine formulations with poly I:C provided a 
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significant protection against VHSV; possibly through an early induction of an anti- viral 
state. Analysis of head kidney immune responses of all vaccine formulations 48 hours 
post-vaccination revealed that pICrgpG formulation conferred the highest induction of 
immune transcripts, upregulating TLR3, TLR8b1, TLR22, IFNs, and ISGs. All 
formulations containing poly I:C, upregulated Mx and ISG15 in zebrafish head kidney. 
Paper V: Effects of dietary n-3 fatty acids on Toll-like receptor activation in primary 
leucocytes from Atlantic salmon (Salmo salar).  
Arnemo M, Kavaliauskis A, Mira MB, Berge GM, Ruyter B, Gjøen T.  
Manuscript submitted for publication. 
The shortage of the n-3 fatty acids EPA and DHA on the international markets has led to 
increasing substitution of fish oil by plant oils in Atlantic salmon feed and thereby 
reducing the EPA and DHA content in the fish. EPA and DHA are known to modulate 
inflammation and immune responses in humans and experimental animals, but the 
minimum required dietary levels for securing fish health are unknown. Atlantic salmon 
were fed diets (growing from 50 to 400 gram) containing 0%, 1% or 2% EPA and DHA 
alone or in combination. Primary head kidney leucocytes were isolated and stimulated with 
TLR ligands to determine if EPA and DHA deficiency can affect expression of important 
immune transcripts and eicosanoid production. Several important genes related to a viral 
immune response did not vary between the groups. However, there was a tendency of the 
non-stimulated cells from high level EPA and DHA groups to express lower levels of IL-
1β. These leucocytes were also more responsive to the TLR agonists, inducing higher 
expression levels of IL-1β and Mx after stimulation. The levels of PGE2 and LTB4 in 
serum and in media from stimulated leucocytes were lowest in both low and high EPA and 
DHA groups. 
Discussion of results
 
 
42 
 
Discussion of results 
The development of efficient and cheap vaccines against aquatic viruses is important for a 
sustainable aquaculture industry. Especially, there is a need for new fish vaccine adjuvants. 
TLRs are important receptors recognising pathogens, and TLR ligands are successfully 
used as adjuvants in human vaccines (Toussi and Massari, 2014, Steinhagen et al., 2011, 
Tomai and Vasilakos, 2012). To benefit the human adjuvant research, increasing the 
knowledge of fish TLR function and their ligands could provide valuable information 
leading to better adjuvant candidates in vaccines against viral diseases in fish. 
I. TLRs and antiviral responses in fish 
To provide overview of the immunostimulatory properties of TLR ligands in Atlantic 
salmon, we stimulated Atlantic salmon primary head kidney leucocytes with a range of 
classical TLR ligands (paper I). Although stimulatory effects in Atlantic salmon have been 
previously reported for certain TLR ligands (Jensen et al., 2002, Strandskog et al., 2008), 
no reports have compared a complete panel of classical ligands for all human TLRs 
(TLR1-9) on Atlantic salmon leucocytes. 
In mammals, TLR3, TLR7, TLR8 and, TLR9 are recognised as the virus-sensing TLRs. 
Trough activation of the transcription factor family IRFs, they induce expression of type I 
IFNs resulting in an antiviral state that provides a crucial first-line defence against viral 
infections (Levy et al., 2001). IFNs lead to expression of ISGs that exert numerous 
antiviral effector functions (Schoggins and Rice, 2011). A group of well-known and 
important ISGs are the Mx proteins, which for example block intracellular viral transport 
and inhibit viral replication (Haller and Kochs, 2002, Lee and Vidal, 2002). The classical 
TLR ligands poly I:C (TLR3) and imiquimod (TLR7) are both widely used as mimics of 
viral infections in mammals and fish. As shown in paper I, these ligands upregulated IFN-
α1, IFN-γ, and Mx expression in the Atlantic salmon leucocytes, suggesting induction of 
an antiviral state. This was confirmed in paper V as both ligands upregulated Mx in 
leucocytes from the “control group”. Additionally, the important pro-inflammatory 
cytokine IL-1β was upregulated in the leucocytes upon exposure to poly I:C and 
imiquimod. Mx and IL-1b were also upregulated by poly I:C in the zebrafish leucocytes 
(paper III). There were some differences in how the zebrafish and Atlantic salmon 
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leucocytes were affected by poly I:C. However, both poly I:C concentration and duration 
of exposure were different in these studies. In addition, the whole head kidney leucocyte 
population was used from zebrafish in paper III, not only the adherent ones as in paper I 
and V. CpG ODNs are well-known to induce antiviral responses in fish and upregulation 
of Mx in vivo (Jørgensen et al., 2003, Strandskog et al., 2008, Carrington and Secombes, 
2006, Jørgensen et al., 2001). Surprisingly, the CpG ODNs used in paper I and V did not 
upregulate Mx in Atlantic salmon head kidney leucocytes, but the IFN-α1 expression was 
increased. 
In paper I we showed that the TLR expression in Atlantic salmon head kidney leucocytes 
was not affected by TLR ligand exposure. However, when analysing the expression of all 
known Atlantic salmon TLRs (at the time) in head kidney from ISAV infected fish, TLR3, 
TLR7, and TLR8a1 were highly upregulated. Atlantic salmon TLR3 was recently shown to 
also be upregulated during IPNV infection (Vidal et al., 2015). In addition to the virus-
sensing TLRs, there are other possible sensors of viruses that may contribute to the 
induction of the antiviral state in the head kidney leucocytes in paper I and V. TLR13, 
TLR21, and TLR22 are also proposed as viral sensors in fish (Matsuo et al., 2008, Pietretti 
and Wiegertjes, 2013, Lee et al., 2014, Yeh et al., 2013, Poynter et al., 2015, Sahoo et al., 
2014), and may contribute to the detection of poly I:C, imiquimod, CpG ODN, or viral 
infection. Also, other viral sensing PRRs, like the RLRs, were not investigated in paper I 
or V, but are probably also involved in sensing dsRNA in fish (see Figure 5) (Kawai and 
Akira, 2008, Poynter et al., 2015). 
The zebrafish has emerged as a powerful model system for studying innate immune 
responses and infectious diseases (Novoa and Figueras, 2012). It is a simpler and cheaper 
model than Atlantic salmon and other aquaculture relevant species. In paper III, we tested 
the in vivo immunostimulatory effects of poly I:C in zebrafish. Six hours after poly I:C 
injection, Mx, TNF-α, and IFNϕ3 were upregulated, but the rest of the analysed genes were 
unchanged.  
Because of the ability of poly I:C to induce strong antiviral responses, it has been widely 
explored as inhibitor of viral infection in fish (e.g. Atlantic salmon, zebrafish, rainbow 
trout, and Japanese flounder). Several reports demonstrate that in vivo prophylactic 
treatment with poly I:C can protect against or delay mortality after challenge with 
important aquatic viruses such as VHSV (Takami et al., 2010), IHNV (Kim et al., 2009, 
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Eaton, 1990), ISAV (Jensen et al., 2002), IPNV (Lockhart et al., 2004) and NNV (Oh et 
al., 2012). The combination of poly I:C with other TLR ligands can also have synergistic 
effects in increasing viral resistance, as demonstrated for CpG ODNs + poly I:C in Atlantic 
salmon (Strandskog et al., 2008, Strandskog et al., 2011) and LPS + poly I:C in zebrafish 
(Ruyra et al., 2014). In paper III, we tested if pre-treatment with poly I:C affected VHSV 
resistance. Consistent with several of the above mentioned studies, poly I:C delayed VHSV 
mortality, probably due to the induction of several genes involved in sensing and 
combating viral infection (TLR3, MDA-5, IRF-3, and Mx).  
The immunostimulatory properties demonstrated in paper, I, III, and V, make poly I:C a 
promising candidate for a new adjuvant in fish virus vaccines. However, the protective 
effect of poly I:C combined with antigen needs to be quantified and compared to existing, 
commonly used vaccines. 
 
Figure 5: Proposed fish nucleic acid PRR signalling pathways. Figure from (Poynter et al., 2015). 
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II. Detecting TLR ligand specificity 
Numerous papers discuss possible TLR ligand specificity in fish, however, the majority of 
the reports are based on gene expression analysis and there are very few functional studies. 
These analyses are often based on the assumption that TLR specificity is conserved 
between mammalian and fish TLRs, hence the use of one or two ligands when studying a 
specific TLR. Some of these receptors may have a wider specificity, and a complete range 
of ligands for mammalian TLRs should be used for initial screening. For the non-
mammalian TLRs, ligands from fish pathogens could be used to detect putative natural 
ligands. It is also difficult to compare available reports since experimental design, 
pathogens, ligands, exposure time, dose of stimulant, and model system (e.g. cell lines, 
primary cells or in vivo) vary.  
Although upregulation of a specific TLR or important immune genes following exposure 
to a TLR ligand, pathogen, or cytokine has been observed, this does not imply receptor-
ligand binding. Many papers report no or only minor changes in TLR expression during 
pathogen, cytokine, or TLR ligand (e.g. in our paper I) (Langevin et al., 2012, Salazar et 
al., 2015, Strandskog et al., 2008, Brietzke et al., 2015, Lee et al., 2014, Palti et al., 2010a). 
The recruitment of cellular factors of innate immunity, rather than induced expression of 
the TLR itself, may be a key role for initiating the immune defence against a pathogen 
(Brietzke et al., 2015). In addition, several studies demonstrate upregulation of a TLR after 
few hours of stimulation with inflammatory cytokines (Lee et al., 2013, Skjæveland et al., 
2009, Skjæveland et al., 2008). It seems that cytokines induce a more rapid upregulation of 
TLRs than the TLR ligands themselves, which suggests that this is an effect of kinetics and 
time of sampling. Cytokines are downstream effector molecules of the TLR signalling 
pathways, and upregulation of TLRs may be a secondary effect of the cytokine induction 
following recognition of the ligands or pathogen tested. 
A direct correlation between ligand or pathogen binding and upregulation of a specific 
TLR is hard to demonstrate, but the upregulation can be considered an indication of a 
functional role for the TLR in recognition of the specific ligand or immune response to a 
certain pathogen.  
The few available molecular tools for studying fish proteins (e.g. antibodies) limit fish 
immunology research; hence the extensive number of gene expression analyses by real-
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time PCR. Although real-time PCR is specific and reproducible for mRNA quantification, 
correlation between mRNA and functional protein levels can vary due to several biological 
factors (e.g. translational efficiency and protein half-life) (Maier et al., 2009). The 
weakness of using real-time PCR as a single method therefore needs to be taken into 
consideration when interpreting gene expression data. 
A common way of detecting ligand specificities for the mammalian TLRs has been in vitro 
reporter assays (Alexopoulou et al., 2001, Hemmi et al., 2002). In these assays, 
transcriptional activity can be measured in cells transfected with the TLR of interest and a 
genetic construct containing  a reporter gene (e.g. luciferase) under the control of a 
promoter of interest (e.g. NF-κB) (Dellacasagrande, 2009). Signalling from all mammalian 
TLRs has been reported to ultimately activate NF-kB factors, and promoters for NF-κB are 
commonly used in reporter plasmids (Kawai and Akira, 2007).  
Our goal was to establish a screening system for ligand specificities of fish TLRs. 
However, this turned out to be difficult, and in paper II we failed to activate rainbow trout 
TLR2 signalling when overexpressed in HEK-293 and salmon CHSE-214 cells. TLR2 
transfected into HEK-293 quenched rather than increased the NF-κB activation in a ligand-
independent fashion, as it has been shown for rainbow trout IRAK4 (Brietzke et al., 2014). 
Although fish TLRs and downstream factors of the TLR cascade seem evolutionary well 
conserved, there are pitfalls when expressing fish TLRs in mammalian cells (e.g. improper 
folding, lack of auxiliary factors or dimerization partner, and sub-optimal temperature). 
However, our efforts to establish the assay in a salmonid cell line did not reconstitute 
robust TLR signalling. Low transfection efficiency and lack of dimerization partners are 
possible explanations for lack of NF-κB activation in the fish cell line. To confirm TLR 
expression in HEK-293 and CHSE-214 when antibodies are not available, TLRs need to be 
tagged, which can interfere with signalling (Pang et al., 2009).  
The literature reveals very few reports that successfully confirm ligand-dependent TLR 
activation of NF-κB or other relevant transcription factors in fish. Fugu TLR3 and TLR22 
were successfully expressed in both HEK-293 and a rainbow trout cell lines, and relayed 
signals to activate IFN expression upon stimulation with dsRNA (Matsuo et al., 2008). The 
rainbow trout TLR5S activated NF-κB in HeLa cells; however, the extracellular domain 
was fused with the intracellular TIR domain of human TLR5 (Tsujita et al., 2004). 
Zebrafish TLR9 and TLR21 have been shown to activate NF-κB in HEK-293 cells, and 
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this activation was increased by co-transfection of Unc93B1, indicating the importance of 
accessory proteins in the reporter assays (Yeh et al., 2013). European common carp TLR2 
could be expressed in HEK-293 and activated by PGN, LTA, and Pam3CSK4 when using 
p38-MAPK phosphorylation as a measure for responsiveness (Ribeiro et al., 2010). 
Although these few reports demonstrate activation of fish TLR in relevant reporter assays, 
from our own and others’ experience, detection of ligand binding of fish TLRs in these 
assays appear very challenging. 
The use of knockout mice is another way of investigating the role of TLRs during infection 
and possible ligand specificity in mammalian TLR research (Akira, 2000). A recent report 
demonstrated that TLR3 and MDA-5 knockdowns in Japanese flounder reduced poly I:C 
mediated antiviral activity (Zhou et al., 2014). In addition, zebrafish embryo TLR2 and 
TLR5 knockdowns displayed inhibited Pam3CK4 and flagellin responses, respectively 
(Yang et al., 2015). The reports demonstrate the importance of these PRRs in immune 
responses induced by the ligands tested. Increased number of tools for laboratory methods 
in fish (e.g. mutants and antibodies) will enhance the future functional studies of fish 
TLRs, their ligands, and signalling pathways. 
III. Poly I:C as vaccine adjuvant   
Adjuvants can be divided into two groups, delivery systems (e.g. emulsions) and 
immunostimulatory components (e.g. PAMPs), and often a combination of the two is 
required. The principle of using PAMPs like poly I:C or other TLR ligands as adjuvants is 
not new to mammalian vaccine research and there are several reviews of their effects 
available (Hafner et al., 2013, Steinhagen et al., 2011, Toussi and Massari, 2014, Tomai 
and Vasilakos, 2012, Martins et al., 2015).  
Poly I:C stimulation in mammals induces a strong type I and III IFN and Th1 cytokine 
response. Poly I:C is a strong Th1-inducing adjuvant that makes it attractive for use in 
vaccines against viruses and other intracellular pathogens, but the responses vary 
depending on cell types, receptors, and cytokines surrounding the administration site 
(Martins et al., 2015).  
Poly I:C has successfully been tested as prophylactic treatment against several important 
aquatic viruses. However, there are only few reports considering the adjuvant effects in a 
fish vaccine. In this thesis, the adjuvant effects of poly I:C in two different VHSV vaccines 
Discussion of results
 
 
48 
 
were tested; one inactivated whole virus vaccine (Paper III) and one subunit vaccine (Paper 
IV). We established the previously described zebrafish cold-water system (Novoa et al., 
2006) to test our vaccine formulations. 
There is no doubt that poly I:C is a strong and efficient antiviral immunostimulant in both 
humans and fish. However, experience from experimental animals and clinical trials shows 
that it can trigger autoimmunity and toxic effects when used systemically and in high 
dosages. In addition, free poly I:C is rapidly degraded by serum nucleases, thus effectively 
reducing the concentration (De Clercq, 1979). More stable derivatives of poly I:C (e.g. 
poly I:C12U and poly ICLC) have been developed in attempts to modulate toxicity, 
immunogenicity and half-life. A commonly used strategy to balance immunogenicity and 
safety is to use a delivery system to optimise activation of antigen presenting cells (without 
excessive systemic effects) at the lowest dosage possible (Hafner et al., 2013, Martins et 
al., 2015). Multiple delivery systems exist (e.g. liposomes, emulsions, alginate, chitosan, 
and PLGA) for use in vaccines (Reed et al., 2013, Hafner et al., 2013). In such a delivery 
system, the antigen and/or immunostimulatory adjuvant (e.g. poly I:C) is encapsulated in a 
nano- or microparticle made up of a biodegradable polymer that allows a slower release of 
the antigen and/or immunostimulatory adjuvants (Griffiths et al., 2010). Several reports 
have demonstrated that the effects of immunostimulants can be enhanced by macrophage 
targeting, using micro- or nanoparticles (Singh et al., 2007). Therefore we tested chitosan-
encapsulated poly I:C in our VHSV vaccines.  
In paper III, chitosan-encapsulated poly I:C was co-injected with inactivated whole VHSV. 
The expression profiles of antiviral TLRs, cytokines, and antiviral proteins in zebrafish 
head kidney suggested strong induction of an antiviral state 48 hours post-vaccination. The 
fish were challenged 31 days later with live VHSV virus (and re-challenged 20 days later). 
The vaccine provided a significant protection against VHSV-induced mortality.  
In paper IV, we tested vaccines containing the VHSV glycoprotein G with either poly I:C 
or chitosan, or a combination of both. The average size of the chitosan-encapsulated poly 
I:C particles was 368 nanometres, thus the name nanoparticles. The early immune 
responses (48 hours post-vaccination) to vaccination was strongest for the vaccine group 
injected with glycoprotein G and free poly I:C. This formulation increased expression of 
antiviral sensors (TLR3, TLR8a1, and TLR22) and IFNs. This is probably due to increased 
free poly I:C leaving the site of injection by the blood stream, whereas the chitosan-
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encapsulated  poly I:C formulation possibly has a depot effect that promotes sustained 
release of poly I:C. All formulations containing poly I:C increased expression of Mx and 
ISG15, and conferred significant protection against VHSV-induced mortality. 
Encapsulating poly I:C in chitosan clearly delayed mortalities compared to free poly I:C, 
although the final mortality was similar in both groups. Poly I:C in combination with CpG 
ODNs has previously been reported to increase the immunogenicity and protection of a 
low dose inactivated SAV vaccine in Atlantic salmon (Thim et al., 2012, Thim et al., 
2014). These studies, combined with results from our vaccination trials, suggest that poly 
I:C is a promising adjuvant candidate for future vaccine formulations containing antigens 
with low immunogenicity. Further, our results also suggest that zebrafish is a valuable 
model for aquaculture-relevant vaccination studies. However, we need to take into account 
that challenge by injection is different from the natural route of viral infection. Future 
studies need to focus on possible adverse effects in the fish upon use of TLR ligands as 
adjuvants.  
Although the injection vaccines have several advantages (e.g. direct delivery of antigen, 
low antigen dose needed, concentrated antigen, protected in highly purified format, and 
refrigerator storage), the method is stressful for the animals, can cause tissue injury, are 
labour intensive, cannot be repeated multiple times during the production cycle (for 
economic reasons), and requires anaesthesia. The ideal vaccine should induce long lasting 
protection starting at an early age and protect the fish throughout the production cycle. 
Compared to injections, oral administration is non-invasive, fish do not need to be handled, 
can be given to fish at any age, will reduce labour cost, and can be repeated (i.g. booster 
dose). However, oral vaccines have proven difficult to develop, and challenges such as low 
immunogenicity, antigen formulation, and storage in high temperature and humidity need 
to be solved.  Mucosal vaccines are beginning to appear for human use, for which chitosan 
seems to be a promising delivery system (Amidi et al., 2010, Smith et al., 2014, van der 
Lubben et al., 2001). Although the vaccine formulation containing chitosan and 
glycoprotein G without poly I:C proved not to be protective in paper IV, several other 
reports have demonstrated chitosan as a potential carrier for antigens delivered via the oral 
route in fish  (Rajesh Kumar et al., 2008, Tian et al., 2008, Rivas-Aravena et al., 2015). 
Since the knowledge of mucosal immunity in fish is increasing (Beck and Peatman, 2015), 
future studies should aim to investigate whether encapsulated TLR ligands (e.g. in 
chitosan) could be used in oral vaccines. 
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IV. Dietary influence on immune responses 
The composition of fatty acids in membrane phospholipids of mammalian immune cells 
strongly correlate with the profile of dietary lipids (Calder, 2013). Membrane 
phospholipids are a part of the microenvironment for leucocyte transmembrane signalling 
receptors and are important substrates for enzymes of eicosanoid metabolism. Due to the 
reduced EPA and DHA content in Atlantic salmon feed, and the subsequent reduction of 
these n-3 fatty acids in the animals, it is important to investigate if the decreased EPA and 
DHA levels can affect immune function and further influence disease resistance and 
vaccine response. Therefore, in paper V, we investigated the effects of EPA and DHA on 
primary head kidney leucocytes from Atlantic salmon. This project is a part of a bigger 
project (“Minimum requirements for omega-3 fatty acids in modern production of Atlantic 
salmon”) in which other partners are investigating the effects of EPA and DHA on growth 
and quality. 
The head kidney is the principal immune organ for phagocytosis and antigen processing in 
fish (Rauta et al., 2012); hence it is rich in immune cells. Our analysis of the head kidney 
confirmed that the EPA and DHA levels in this tissue correlated with the dietary levels of 
these fatty acids. This correlation is widely recognised in mammals (Calder, 2013), but has 
also previously been demonstrated in several fish species (Bell et al., 1993, Bell et al., 
1992, Bell et al., 1996, Bell et al., 1998, Ganga et al., 2005). In order to investigate the role 
of altered fatty acid composition in head kidney on immune function, we isolated head 
kidney leucocytes from Atlantic salmon that had been fed various levels of EPA and DHA. 
The leucocytes were stimulated with TLR ligands (as in paper I) or infected with viruses 
(ISAV and IPNV) and analysed for expression of important immune genes. The majority 
of the genes analysed in non-stimulated leucocytes were not affected by dietary EPA and 
DHA, but IL-1β was expressed at lower levels in the high EPA and DHA dietary groups, 
thus indicating anti-inflammatory effects (like widely recognised in mammals (Calder, 
2013)). However, after stimulation with TLR ligands, leucocytes from fish that had been 
fed low EPA and DHA were unable to upregulate the important immune transcripts IL-1β 
and Mx1, which indicates that the absence of dietary EPA and DHA may have 
immunosuppressive effects. The reduced response to the mimics of bacterial and viral 
infection could potentially make these fish more prone to infections. In addition, vaccine 
effects in these fish can potentially be reduced (e.g. if poly I:C is used as adjuvant).  
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Even though replacement of fish oil by vegetable oil is an important topic, there are few 
studies focussing on its effect on disease resistance and vaccine effects (most studies focus 
on the effects on growth and quality). There are a few studies on Atlantic salmon, where 
partial or full replacement of fish oil by vegetable oils did not appear to affect vaccination 
efficacy (Montero and Izquierdo, 2010). There is a disagreement in the existing literature 
about n-3 fatty acids and infectious disease resistance in mammals (Anderson and Fritsche, 
2002) and fish. Some in vitro studies indicate that low n-3 fatty acids decrease disease 
resistance in fish (decreased phagocytosis, bacterial clearance, and respiratory burst) 
(Kiron et al., 1995, Sheldon and Blazer, 1991, Montero et al., 2008, Montero et al., 2003), 
while others report no effect of low EPA and DHA on leucocyte activity (Seierstad et al., 
2009, Montero et al., 2003, Gjøen et al., 2004). In vivo experiments have also produced 
different outcomes, in which dietary vegetable oils have been demonstrated to decrease, 
increase, or show no effects on mortality after bacterial challenge (Waagbø, 1994, 
Thompson et al., 1996, Gjøen et al., 2004, Montero and Izquierdo, 2010). Since the study 
design and feed content varies highly among available reports, it is difficult to explain the 
contradictory results. Our data indicated that higher tissue levels of EPA and DHA confers 
increased sensitivity in leucocytes stimulated with TLR agonists. This supports the 
previous findings that demonstrate that n-3 fatty acids are important for diseases resistance. 
However, further research is required to understand the role of dietary fatty acids on 
resistance to pathogens and immunostimulants in fish. 
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Main conclusions 
¾ Head kidney and spleen are the main TLR expressing tissues in Atlantic salmon. 
Several TLR ligands induced expression of inflammatory cytokines in salmon head 
kidney leucocytes. The TLR3 ligand poly I:C, induced expression of antiviral 
transcripts in primary head kidney leucocytes. TLR3, TLR7, and TLR8a1 were 
induced in vivo after viral infection. 
¾ Although rainbow trout TLR2 domain structure and ligand-binding sites seemed to 
be evolutionarily conserved, classical TLR2 ligands failed to activate TLR2 
signalling in vitro. 
¾ Poly I:C induced expression of antiviral transcripts in zebrafish both in vitro and in 
vivo, and delayed mortality after VHSV challenge. 
¾ Poly I:C formulated with chitosan co-injected with inactivated VHSV provided 
protection against subsequent VHSV infection in zebrafish. Also, poly I:C alone or 
combined with chitosan co-injected with recombinant VHSV glycoprotein G 
provided protection against VHSV. 
¾ Although few genes were affected by EPA and DHA in the non-stimulated 
leucocytes, the ability of these leucocytes to respond to TLR ligand stimuli was 
reduced with low dietary and head kidney levels of EPA and DHA, thus indicating 
the importance of n-3 fatty acids in resistance to infection and response to vaccines. 
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